Avantor, Inc. (AVTR)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Avantor, Inc. keeps $2 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Avantor’s adjusted EPS of $0.21 topped the $0.19 estimate by 9.7%, and revenue of about $1.7 billion beat the $1.6 billion consensus by 5.1% in the second fiscal quarter of 2026, reported July 29, based on preliminary results. Revenue rose about 1% from $1.68 billion a year ago, with gross profit of about $537 million leaving gross margin near 32% and operating margin around 7%. Adjusted EPS fell about 13% from $0.24 a year ago, while net income came to about $38.1 million, down about 41% from roughly $64.7 million a year ago; operating cash flow was about $17.4 million. For the next period, consensus calls for EPS of $0.20 on revenue of $1.64 billion.
About Avantor, Inc.
Avantor, Inc. trades on the NYSE as AVTR and supplies the healthcare research and production market with laboratory materials, equipment, and support services across the broader medical tools and supplies business. Across this medical tools and supplies business, it generated $6.6 billion of revenue in FY2025.
Today's Snapshot
AVTR closed 2.4% lower at 14.88.
Trading Volume
Above 10d avg 7.5M
7.8M
vs S&P 500 Today
Underperforming Market
-1.95%
Updated: September 10, 2026 at 12:10 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.47 - $14.74Buy
- RSI (14)62.53Neutral
- Stochastic %K (14, 3, 3)80.94Sell
- MACD Level (12, 26)0.61Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.